Stock analysis · Bull Rankings model

CRNX analysis

Crinetics Pharmaceuticals Inc — Pharmaceuticals. Scored on the same transparent 7-signal model behind the daily rankings.

★
CRNX
Crinetics Pharmaceuticals Inc · Pharmaceuticals
FCF-$420mF
Rev+2277.5%A
D/E0.05A
P/S214.7xD
PEG——
61Score
$36.78
1Y Target$49.65Near-term target
5Y Target$73.98Compound horizon
10Y Target$192.50Long-dated conviction
FCF-$420mTTM · 03/26
F
FCF is negative (-$420m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+2277.5%TTM YoY
A
Revenue +2277.5% — hypergrowth, top decile
D/E0.05total
A
D/E 0.05 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S214.7x
D
P/S 214.7x — extreme, prices in flawless execution
PEG—proxy
—
PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Pharmaceuticals · market cap $3.9b. Down 37% from 52-week high of $57.99 — deep drawdown territory. Revenue growing +2278% — in hypergrowth territory.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$420m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -2747.2%) — path to GAAP profitability is the core thesis risk. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $49.65 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $73.98 — requires the platform / technology to reach commercial scale. 10 yr $192.50 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · CRNX
Shares to buy
54
Position size
$1,986
4.0% of portfolio
Stop price
$27.59
25% below $36.78
$ at risk
$500.00
1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Analyze another ticker →